346 related articles for article (PubMed ID: 18187663)
1. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
2. Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.
Xiaowen H; Yi S
Mol Biol Rep; 2012 Sep; 39(9):8763-70. PubMed ID: 22707197
[TBL] [Abstract][Full Text] [Related]
3. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
4. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway.
Huang M; Zhang H; Liu T; Tian D; Gu L; Zhou M
Mol Cancer Ther; 2013 Feb; 12(2):184-94. PubMed ID: 23243057
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
7. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F
Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616
[TBL] [Abstract][Full Text] [Related]
8. Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma.
Clawson KA; Borja-Cacho D; Antonoff MB; Saluja AK; Vickers SM
J Surg Res; 2010 Oct; 163(2):244-9. PubMed ID: 20691980
[TBL] [Abstract][Full Text] [Related]
9. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358
[TBL] [Abstract][Full Text] [Related]
10. Triptolide induces apoptosis of gastric cancer cells via inhibiting the overexpression of MDM2.
Wang BY; Cao J; Chen JW; Liu QY
Med Oncol; 2014 Nov; 31(11):270. PubMed ID: 25280518
[TBL] [Abstract][Full Text] [Related]
11. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
Cancer Lett; 2014 Jun; 348(1-2):156-66. PubMed ID: 24662747
[TBL] [Abstract][Full Text] [Related]
12. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.
Matsui Y; Watanabe J; Ikegawa M; Kamoto T; Ogawa O; Nishiyama H
Oncogene; 2008 Jul; 27(33):4603-14. PubMed ID: 18391982
[TBL] [Abstract][Full Text] [Related]
13. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.
Carter BZ; Mak DH; Shi Y; Fidler JM; Chen R; Ling X; Plunkett W; Andreeff M
Leukemia; 2012 Mar; 26(3):443-50. PubMed ID: 21904380
[TBL] [Abstract][Full Text] [Related]
14. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
Park EJ; Choi KS; Yoo YH; Kwon TK
Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway.
Hu L; Wang Y; Chen Z; Fu L; Wang S; Zhang X; Zhang P; Lu X; Jie H; Li M; Wang Y; Liu Z
Oxid Med Cell Longev; 2019; 2019():9675450. PubMed ID: 31019655
[TBL] [Abstract][Full Text] [Related]
16. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation.
Lee KY; Park JS; Jee YK; Rosen GD
Exp Mol Med; 2002 Dec; 34(6):462-8. PubMed ID: 12526088
[TBL] [Abstract][Full Text] [Related]
17. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.
Zhou J; Lu X; Tan TZ; Chng WJ
Mol Oncol; 2018 Jan; 12(1):33-47. PubMed ID: 29063676
[TBL] [Abstract][Full Text] [Related]
18. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
[TBL] [Abstract][Full Text] [Related]
19. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
Tazzari PL; Tabellini G; Ricci F; Papa V; Bortul R; Chiarini F; Evangelisti C; Martinelli G; Bontadini A; Cocco L; McCubrey JA; Martelli AM
Cancer Res; 2008 Nov; 68(22):9394-403. PubMed ID: 19010914
[TBL] [Abstract][Full Text] [Related]
20. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]